Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/jev2.12092 http://scihub22266oqcxt.onion/10.1002/jev2.12092 34122778!8172627!34122778     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Extracell+Vesicles 2021 ; 10 (8): e12092 Nephropedia Template TP {{tp|p=34122778|t=2021. Early prediction of COVID-19 severity using extracellular vesicle COPB2 |pdf=|usr=}}{{34122778}} gab.com Text Early prediction of COVID-19 severity using extracellular vesicle COPB2 JO: J Extracell Vesicles http://www.kidney.de/pget.php?&tw=1&pmid=34122778 #FOAvip The clinical manifestations of COVID-19 vary broadly, ranging from asymptomatic infection to acute respiratory failure and death. But the predictive biomarkers for characterizing the variability are still lacking. Since emerging evidence indicates that extracellular vesicles (EVs) and extracellular RNAs (exRNAs) are functionally involved in a number of pathological processes, we hypothesize that these extracellular components may be key determinants and/or predictors of COVID-19 severity. To test our hypothesis, we collected serum samples from 31 patients with mild COVID-19 symptoms at the time of their admission for discovery cohort. After symptomatic treatment without corticosteroids, 9 of the 31 patients developed severe/critical COVID-19 symptoms. We analyzed EV protein and exRNA profiles to look for correlations between these profiles and COVID-19 severity. Strikingly, we identified three distinct groups of markers (antiviral response-related EV proteins, coagulation-related markers, and liver damage-related exRNAs) with the potential to serve as early predictive biomarkers for COVID-19 severity. As the best predictive marker, EV COPB2 protein, a subunit of the Golgi coatomer complex, exhibited significantly higher abundance in patients remained mild than developed severe/critical COVID-19 and healthy controls in discovery cohort (AUC 1.00 (95% CI: 1.00-1.00)). The validation set included 40 COVID-19 patients and 39 healthy controls, and showed exactly the same trend between the three groups with excellent predictive value (AUC 0.85 (95% CI: 0.73-0.97)). These findings highlight the potential of EV COPB2 expression for patient stratification and for making early clinical decisions about strategies for COVID-19 therapy. Twit Text FOAVip Early prediction of COVID-19 severity using extracellular vesicle COPB2 ????J Extracell Vesicles http://www.kidney.de/pget.php?&tw=1&pmid=34122778 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34122778 #FOAvip English Wikipedia <ref>{{Cite pmid|34122778}}</ref> Early prediction of COVID-19 severity using extracellular vesicle COPB2 #MMPMID34122778 Fujita Y; Hoshina T; Matsuzaki J; Yoshioka Y; Kadota T; Hosaka Y; Fujimoto S; Kawamoto H; Watanabe N; Sawaki K; Sakamoto Y; Miyajima M; Lee K; Nakaharai K; Horino T; Nakagawa R; Araya J; Miyato M; Yoshida M; Kuwano K; Ochiya T J Extracell Vesicles 2021[Jun]; 10 (8): e12092 PMID34122778show ga The clinical manifestations of COVID-19 vary broadly, ranging from asymptomatic infection to acute respiratory failure and death. But the predictive biomarkers for characterizing the variability are still lacking. Since emerging evidence indicates that extracellular vesicles (EVs) and extracellular RNAs (exRNAs) are functionally involved in a number of pathological processes, we hypothesize that these extracellular components may be key determinants and/or predictors of COVID-19 severity. To test our hypothesis, we collected serum samples from 31 patients with mild COVID-19 symptoms at the time of their admission for discovery cohort. After symptomatic treatment without corticosteroids, 9 of the 31 patients developed severe/critical COVID-19 symptoms. We analyzed EV protein and exRNA profiles to look for correlations between these profiles and COVID-19 severity. Strikingly, we identified three distinct groups of markers (antiviral response-related EV proteins, coagulation-related markers, and liver damage-related exRNAs) with the potential to serve as early predictive biomarkers for COVID-19 severity. As the best predictive marker, EV COPB2 protein, a subunit of the Golgi coatomer complex, exhibited significantly higher abundance in patients remained mild than developed severe/critical COVID-19 and healthy controls in discovery cohort (AUC 1.00 (95% CI: 1.00-1.00)). The validation set included 40 COVID-19 patients and 39 healthy controls, and showed exactly the same trend between the three groups with excellent predictive value (AUC 0.85 (95% CI: 0.73-0.97)). These findings highlight the potential of EV COPB2 expression for patient stratification and for making early clinical decisions about strategies for COVID-19 therapy. |Biomarkers/blood[MESH] |COVID-19/*blood/immunology/*physiopathology[MESH] |Cell-Free Nucleic Acids/*blood[MESH] |Coatomer Protein/*blood[MESH] |Extracellular Vesicles/*chemistry[MESH] |Humans[MESH] |Retrospective Studies[MESH] |SARS-CoV-2/physiology[MESH]Early prediction of COVID-19 severity using extracellular vesicle COPB(epmc).pdf DeepDyve Pubget Overpricing